5.02 -0.01 (-0.2%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 6.88 | 1-year : | 7.63 |
Resists | First : | 5.89 | Second : | 6.53 |
Pivot price | 5.29 | |||
Supports | First : | 4.84 | Second : | 4.02 |
MAs | MA(5) : | 4.99 | MA(20) : | 5.44 |
MA(100) : | 5.59 | MA(250) : | 7.41 | |
MACD | MACD : | -0.2 | Signal : | -0.2 |
%K %D | K(14,3) : | 10.7 | D(3) : | 8.5 |
RSI | RSI(14): 41 | |||
52-week | High : | 12.75 | Low : | 4.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SCPH ] has closed above bottom band by 22.8%. Bollinger Bands are 2.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 5.16 - 5.19 | 5.19 - 5.22 |
Low: | 4.9 - 4.93 | 4.93 - 4.96 |
Close: | 4.97 - 5.03 | 5.03 - 5.07 |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Wed, 27 Mar 2024
Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62% - Yahoo Finance
Wed, 27 Mar 2024
American Century Companies Inc. Sells 15647 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Mon, 25 Mar 2024
scPharmaceuticals Inc. (NASDAQ:SCPH) stock most popular amongst private equity firms who own 41%, while ... - Yahoo Movies UK
Mon, 18 Mar 2024
Research Analysts Offer Predictions for scPharmaceuticals Inc.'s FY2028 Earnings (NASDAQ:SCPH) - Defense World
Sat, 16 Mar 2024
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts - Simply Wall St
Wed, 13 Mar 2024
scPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growth - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 36 (M) |
Shares Float | 18 (M) |
Held by Insiders | 6.9 (%) |
Held by Institutions | 75.9 (%) |
Shares Short | 4,790 (K) |
Shares Short P.Month | 4,670 (K) |
EPS | -1.42 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.02 |
Profit Margin | 0 % |
Operating Margin | -250.3 % |
Return on Assets (ttm) | -31.7 % |
Return on Equity (ttm) | -100 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.37 |
EBITDA (p.s.) | -1.54 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -59 (M) |
Levered Free Cash Flow | -40 (M) |
PE Ratio | -3.54 |
PEG Ratio | 0 |
Price to Book value | 4.87 |
Price to Sales | 13.31 |
Price to Cash Flow | -3.06 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |